[go: up one dir, main page]

AR124189A1 - Compuestos y procedimientos de uso de los mismos - Google Patents

Compuestos y procedimientos de uso de los mismos

Info

Publication number
AR124189A1
AR124189A1 ARP210103314A ARP210103314A AR124189A1 AR 124189 A1 AR124189 A1 AR 124189A1 AR P210103314 A ARP210103314 A AR P210103314A AR P210103314 A ARP210103314 A AR P210103314A AR 124189 A1 AR124189 A1 AR 124189A1
Authority
AR
Argentina
Prior art keywords
independently
alkyl
optionally substituted
occurrence
aryl
Prior art date
Application number
ARP210103314A
Other languages
English (en)
Inventor
Jakob Fuhrmann
Nicholas John Skelton
Peter Scott Dragovich
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR124189A1 publication Critical patent/AR124189A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a compuestos y composiciones farmacéuticas de los mismos, y procedimientos de uso de los compuestos y las composiciones en terapia, tales como los procedimientos para tratar el cáncer. Reivindicación 1: Un compuesto de fórmula (1) o un estereoisómero o tautómero del mismo, o una sal farmacéuticamente aceptable de cualquiera de los anteriores, en el que: I) L¹-R¹ es metilo; L² es un enlace o alquilo C₁₋₁₂; R² es i) -O-arilo C₆₋₂₀, opcionalmente sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, halo; ii) heterociclilo de 4 - 20 miembros, opcionalmente sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, -C(O)O-alquilo C₁₋₆; iii) heteroarilo de 5 - 20 miembros, en el que el heteroarilo de 5 - 20 miembros de R² está sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, halo, alquilo C₁₋₁₂; iv) cicloalquilo C₆₋₂₀, opcionalmente sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, -C(O)O-alquilo C₁₋₆; o II) L²-R² es ciclopropilo; L¹ es un enlace o alquilo C₁₋₁₂; en el que el alquilo C₁₋₁₂ de L¹ está opcionalmente sustituido con uno o más Rᵉ; en el que Rᵉ es, independientemente en cada caso, alquilo C₁₋₆ o hidroxilalquilo C₁₋₆; R¹ es i) -L³-arilo C₆₋₂₀; en el que L³ es O ó C(O)NH; el arilo C₆₋₂₀ de -L³-arilo C₆₋₂₀ está opcionalmente sustituido con uno o más Rˢ, en el que Rˢ es, independientemente en cada caso, haloalquilo C₁₋₆; ii) -cicloalquilo C₄₋₂₀ opcionalmente sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, halo, heteroarilo de 5 - 20 miembros o S(O)alquilo C₁₋₆; iii) -arilo C₆₋₂₀, opcionalmente sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, halo, ciano, o heteroarilo de 5 - 20 miembros; en el que el heteroarilo de 5 - 20 miembros de Rˢ tiene uno más átomos anulares, seleccionados independientemente de N y O; y en el que el heteroarilo de 5 - 20 miembros de Rˢ está opcionalmente sustituido con uno o más Rᵗ; en el que Rᵗ es, independientemente en cada caso, alquilo C₁₋₆; iv) -heteroarilo de 5 - 20 miembros, opcionalmente sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, halo, amina, alquilo C₁₋₆, o arilo C₆₋₂₀; en el que el arilo C₆₋₂₀ de Rˢ está opcionalmente sustituido con uno o más Rᵗ; en el que Rᵗ es, independientemente en cada caso, halo; o v) -heterociclilo de 4 - 20 miembros, opcionalmente sustituido con uno o más Rˢ; en el que Rˢ es, independientemente en cada caso, halo, oxo, hidroxilo, heteroarilo de 5 - 20 miembros, arilo C₆₋₂₀, o alquilo C₁₋₆; en el que el alquilo C₁₋₆ de Rˢ está opcionalmente sustituido con uno o más Rᵗ; en el que Rᵗ es, independientemente en cada caso, arilo C₆₋₂₀, en el que el arilo C₆₋₂₀ de Rˢ está opcionalmente sustituido con uno o más Rᵘ; en el que Rᵘ es, independientemente en cada caso, halo, alquilo C₁₋₆. Reivindicación 20: Una composición farmacéutica que comprende un compuesto de una cualquiera de las reivindicaciones 1 - 19, o un estereoisómero o tautómero del mismo, o una sal farmacéuticamente aceptable de cualquiera de los anteriores, y uno o más excipientes farmacéuticamente aceptables.
ARP210103314A 2020-11-30 2021-11-30 Compuestos y procedimientos de uso de los mismos AR124189A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063119621P 2020-11-30 2020-11-30

Publications (1)

Publication Number Publication Date
AR124189A1 true AR124189A1 (es) 2023-02-22

Family

ID=79601972

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103314A AR124189A1 (es) 2020-11-30 2021-11-30 Compuestos y procedimientos de uso de los mismos

Country Status (6)

Country Link
US (1) US20230295145A1 (es)
EP (1) EP4251619A1 (es)
JP (1) JP2023551290A (es)
CN (1) CN116761797A (es)
AR (1) AR124189A1 (es)
WO (1) WO2022115879A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814367B2 (en) 2021-03-15 2023-11-14 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof
WO2024102986A2 (en) * 2022-11-10 2024-05-16 The Texas A&M University System Sars-cov-2 mpro inhibitors
WO2024211154A2 (en) * 2023-04-03 2024-10-10 Wisconsin Alumni Research Foundation Ferritin-targeting protacs and methods of inducing pyroptosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CA2861066C (en) * 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
WO2019084030A1 (en) * 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) * 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof

Also Published As

Publication number Publication date
US20230295145A1 (en) 2023-09-21
EP4251619A1 (en) 2023-10-04
WO2022115879A1 (en) 2022-06-02
JP2023551290A (ja) 2023-12-07
TW202237587A (zh) 2022-10-01
CN116761797A (zh) 2023-09-15

Similar Documents

Publication Publication Date Title
BR112022010383A2 (pt) Compostos tricíclicos substituídos
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
AR124189A1 (es) Compuestos y procedimientos de uso de los mismos
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
AR119728A1 (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR109108A1 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
AR098844A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2021009206A (es) Terapias contra el cancer.
AR120649A1 (es) Antagonistas del receptor de crf y métodos de uso
AR086029A1 (es) Compuesto derivado de fenil-isoxazol, metodo para prepararlo, composiciones y combinaciones que lo comprende, su uso para preparar una composicion farmaceutica para el tratamiento o la prevencion de infecciones virales y metodo para prevenir tales tratamientos o prevenciones
PH12020500572A1 (en) Substituted alkynylene compounds as anticancer agents
AR107937A1 (es) Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR109042A1 (es) COMPUESTOS MODULARES DE RORg
AR120273A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR106720A1 (es) Compuestos de quinazolina 2-sustituida que comprenden un grupo heterocíclico sustituido y métodos de uso de los mismos